A week prior to the closing date Human Genome Sciences (HGS) have fixed for prospective buyers to submit bids, HGS have announced that US regulators are to review raxibacumab again for the treatment’s previously-rejected anthrax medication. The US Food and Drug Administration (FDA) have confirmed the receipt of the resubmission of the Biologics License Application
GlaxoSmithKline (GSK) has prolonged their proposition to acquire Human Genome Sciences (HGS) without increasing their $2.60 billion offer, after barely any shares were offered. The UK drugs giant has delayed the expiration date to June 29th for their unsolicited tender offer to acquire all the remaining common shares of Human Genome Sciences at $13.00 each.
GlaxoSmithKline (GSK) wants to change the whole board of Human Genome Sciences (HGS), according to a Reuters report, and contenders from across the sector have been approached. The news agency, states that GSK will pursue the assistance from Human Genome Sciences shareholders to exchange the board with 12 independent directors. They claim that the UK drugs
Human Genome Sciences (HGS) on Thursday adopted a shareholder rights plan to confront GlaxoSmithKline’s hostile bid, and discharged the GSK’s $2.60 billion proposition as insufficient. A week ago, GlaxoSmithKline (GSK) appealed directly to shareholders, after initially being rejected by HGS last month, with the $13-a-share proposition for GSK’s long-time partner and co-developer of the lupus
GSK’s (GlaxoSmithKline’s) $2.60 billion bid to buy Human Genome Sciences (HGS) has taken a hostile direction, with GSK directly approaching shareholders with their previously-declined offer, instead of participating in HGS’ “strategic alternatives review”. Last month, the board at Human Genome Sciences, which developed Benlysta (belimumab) with GSK, rejected GSK’s $13.00 per share offer, which signified
In a milestone decision for the pharmaceutical and biotechnology industries, the UK’s Supreme Court yesterday ruled against Eli Lilly and upheld a patent on a gene sequence held by Human Genome Sciences relating to its new GlaxoSmithKline-partnered lupus drug Benlysta. Judge David Hope commented that “the supreme court unanimously allows the appeal … and remits